SAN CARLOS, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next-generation, potentially curative cell ...
Dyno Therapeutics announces exercise of option by Roche for next-generation AAV vector for neurological gene therapy ...
Phase 2 clinical study of firicabtagene autoleucel (firi-cel); Interim analysis results expected to be reported in 1H'25 - - IND application for CRG-023 ...
4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway
Strategically focused pipeline optimizes resource allocation to progress two product candidates with strongest clinical proof of concept: 4D-150 for wet AMD and DME and 4D-710 for cystic fibrosis ...
Open source software (OSS) is a prime target for supply chain cyberattacks and protecting it remains a major challenge.
NDAQ:FDMT) 4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path ...
PBFT02 demonstrated durable, elevated CSF PGRN levels and early evidence of reduction in plasma <a target=_blank href= ...
Grand Challenges Canada, in partnership with the Science for Africa Foundation, the Global Grand Challenges Network, and The ...
Grand Challenges Canada, Science for Africa Foundation, Global Grand Challenges Network, and Geneva Learning Foundation launch global survey to collect insights on climate and health - TORONTO ...
"It is my pleasure to welcome Nishant to the Jeune team,” said Krish S. Krishnan, Chairman and CEO of Krystal Biotech and ...
Continued Focus on Driving Advancement of TN-201 and TN-401 Gene Therapies for Cardiomyopathies Dosing Initiated in Cohort 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback